Hims & Hers Takes On Novo Nordisk: What We Know Right Now

MrDecoder · 2026-03-09T17:26:05+00:00

Hims & Hers has launched a new oral GLP-1 product, leveraging a legal loophole similar to its injectable GLP-1s, causing concern for Novo Nordisk, which recently released its own oral version of Wegovy.

MrDecoder

2026-03-09 17:26:05

Abstract generation in progress

Hims & Hers (HIMS +37.04%) introduced a new oral GLP-1 product this morning only weeks after Novo Nordisk’s (NVO +0.78%) hit oral version of Wegovy hit the market. And the pharma giant wasn’t happy with what they heard.

Ad the day has gone on we’ve learned more about how Hims & Hers may be producing a compounded version of this GLP-1 and how it’ll use a legal loophole to keep the product in the market, just like it did with injectable GLP-1s.

*Stock prices used were end-of-day prices of Feb. 5, 2026. The video was published on Feb. 5, 2026.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

2 Likes